Best-sell­ing Tagris­so fur­ther out­paces an up­com­ing J&J ri­val, win­ning ap­proval in new NSCLC in­di­ca­tion

As­traZeneca’s flag­ship can­cer drug is adding a new in­di­ca­tion to its fleet.

Fri­day af­ter­noon, the FDA grant­ed Tagris­so the thumbs-up in non-small cell lung can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER